Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence F Eichenfield

Showing results (261-270 of 376) with videos related to

Pageof 38
Sort By:
Journal of the American Academy of Dermatology|December 27, 2022
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.
Dermatology (Basel, Switzerland)|October 15, 2024
Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert ConsensusLawrence F Eichenfield, Mark Boguniewicz, Christine T Lauren, et al.
The New England Journal of Medicine|January 18, 2008
Etanercept treatment for children and adolescents with plaque psoriasisAmy S Paller, Elaine C Siegfried, Richard G Langley, et al.
Journal of Drugs in Dermatology : JDD|March 5, 2015
Evolving perspectives on the etiology and pathogenesis of acne vulgarisLawrence F Eichenfield, James Q Del Rosso, Anthony J Mancini, et al.
Journal of the American Academy of Dermatology|August 22, 2017
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitisLawrence F Eichenfield, Robert S Call, Douglass W Forsha, et al.
Journal of the American Academy of Dermatology|November 19, 2016
Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT surveyChristine R Totri, Lawrence F Eichenfield, Kirsty Logan, et al.
Allergy and Asthma Proceedings|May 16, 2012
Effect of cat and daycare exposures on the risk of asthma in children with atopic dermatitisJonathan M Gaffin, Jonathan M Spergel, Mark Boguniewicz, et al.
Pediatrics|August 5, 2015
Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care ProvidersLawrence F Eichenfield, Mark Boguniewicz, Eric L Simpson, et al.
Journal of the American Academy of Dermatology|May 19, 2016
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled studyJon M Hanifin, Charles N Ellis, Ilona J Frieden, et al.
Journal of the American Academy of Dermatology|December 6, 2022
Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trialLisa A Beck, Thomas Bieber, Stephan Weidinger, et al.
Pageof 38

Showing results (261-270 of 376) with videos related to

Sort By:
Pageof 38
Journal of the American Academy of Dermatology|December 27, 2022
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.
Dermatology (Basel, Switzerland)|October 15, 2024
Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert ConsensusLawrence F Eichenfield, Mark Boguniewicz, Christine T Lauren, et al.
The New England Journal of Medicine|January 18, 2008
Etanercept treatment for children and adolescents with plaque psoriasisAmy S Paller, Elaine C Siegfried, Richard G Langley, et al.
Journal of Drugs in Dermatology : JDD|March 5, 2015
Evolving perspectives on the etiology and pathogenesis of acne vulgarisLawrence F Eichenfield, James Q Del Rosso, Anthony J Mancini, et al.
Journal of the American Academy of Dermatology|August 22, 2017
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitisLawrence F Eichenfield, Robert S Call, Douglass W Forsha, et al.
Journal of the American Academy of Dermatology|November 19, 2016
Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT surveyChristine R Totri, Lawrence F Eichenfield, Kirsty Logan, et al.
Allergy and Asthma Proceedings|May 16, 2012
Effect of cat and daycare exposures on the risk of asthma in children with atopic dermatitisJonathan M Gaffin, Jonathan M Spergel, Mark Boguniewicz, et al.
Pediatrics|August 5, 2015
Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care ProvidersLawrence F Eichenfield, Mark Boguniewicz, Eric L Simpson, et al.
Journal of the American Academy of Dermatology|May 19, 2016
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled studyJon M Hanifin, Charles N Ellis, Ilona J Frieden, et al.
Journal of the American Academy of Dermatology|December 6, 2022
Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trialLisa A Beck, Thomas Bieber, Stephan Weidinger, et al.
Pageof 38